Yi Wan Lim

PXR, CAR and HNF4α genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients

S Y Hor, S C Lee, Christin Wong et al. · The Pharmacogenomics Journal · 2007 · 56 citations

Pharmacology, Pharmacotherapy, Pharmacogenomics +4

Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers

Gloria Chan, Pei Yi Ong, Jeffrey Low et al. · Oncotarget · 2018 · 43 citations · Full text

A multicenter phase II randomized trial of durvalumab (D) versus physician’s choice chemotherapy (PCC) in patients (pts) with recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3).

David S.P. Tan, Chel Hun Choi, Natalie Y.L. Ngoi et al. · Journal of Clinical Oncology · 2022 · 26 citations

Medicine, Metronomic Therapy, Immunology +15

Pharmacokinetics and pharmacodynamics of docetaxel with or without ketoconazole modulation in chemonaive breast cancer patients

Yi Wan Lim, Brian C. Goh, L.-Z. Wang et al. · Annals of Oncology · 2010 · 24 citations · Full text

Medicine, Pharmacology, Ketoconazole Modulation +7

Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer

Natalie Y.L. Ngoi, Valerie Heong, X.W. Lee et al. · Gynecologic Oncology Reports · 2018 · 14 citations · Full text